MedTrace Logo

Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis

NCT00425932 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2013-08-22

No results posted yet for this study

Summary

The purpose of this study is to further investigate rituximab in the treatment of rheumatoid arthritis and to evaluate magnetic resonance imaging of the joints as a possible method to improve the evaluation of treatments.

Conditions

Interventions

BIOLOGICAL

Rituximab

At Week 24 or any time up to Week 48 if the Patient DAS 28 \> 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.

Sponsors & Collaborators

  • Oklahoma Medical Research Foundation

    collaborator OTHER

  • Genentech, Inc.

    collaborator INDUSTRY

  • Gaylis, Norman B., M.D.

    lead INDIV

Principal Investigators

  • Norman B Gaylis, MD · Arthritis & Rheumatic Disease Specialties

  • Ewa Olech, M.D. · Oklahoma Medical Research Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2011-11-30
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00425932 on ClinicalTrials.gov